Manchester Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Manchester Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-26,880	Closed	-$201K	–	1034
2023 Q2	$201K	Hold	26,880	–	–	0.03%	272
2023 Q1	$179K	Hold	26,880	–	–	0.02%	298
2022 Q4	$207K	Hold	26,880	–	–	0.03%	248
2022 Q3	$286K	Buy	26,880 +13,440	+100%	+$136K	0.05%	179
2022 Q2	$109K	Hold	13,440	–	–	0.02%	284
2022 Q1	$96K	Buy	+13,440	New	+$143K	0.01%	342

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Manchester Capital Management's RXRX Position: Q3 2023 in Review

Manchester Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q3 2023, closing a stake of 26,880 shares — an estimated $201K sold.

Manchester Capital Management first reported a position in RXRX in Q1 2022 and held it in 6 quarters. The position peaked at $286K in Q3 2022. 192 funds tracked by Wall St. Rank hold RXRX as of Q3 2023.

Manchester Capital Management reported no remaining Recursion Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Manchester Capital Management sold 26,880 Recursion Pharmaceuticals shares in Q3 2023, an estimated $201K.
Manchester Capital Management first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 6 quarters.
Manchester Capital Management's Recursion Pharmaceuticals position peaked at $286K in Q3 2022.
192 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2023.

Based on Manchester Capital Management's 13F filing for Q3 2023, filed 9 Nov 2023.